Participate in a Groundbreaking Non-Invasive Imaging Trial
A diagnosis of HR-/HER2+ breast cancer can be scary, and identifying the right course of action is overwhelming. That’s why research is so important!
BAMF Health is at the forefront of research. We are launching a non-invasive imaging clinical trial for those with HR-/HER2+ metastatic breast cancer. This trial aims to understand the prevalence of a specific biomarker in this subset of breast cancer. We invite you to apply.
Women with breast cancer deserve more options—help us get there faster.
Eligibility and Benefits
Eligibility Criteria
- At least 18 years old
- Diagnosed with HR-/HER2+ metastatic breast cancer
- At least one measurable tumor lesion on conventional imaging
- Women of childbearing potential must have a negative pregnancy test
Benefits to Participating
- Receive an advanced PET scan at BAMF Health
- Images will be sent to your doctor
- $500 stipend provided
- The opportunity to advance options for women diagnosed with breast cancer
Let's Advance Research Together!
BAMF Health Clinical Trial Updates
BAMF Health Doses First Patient in the U.S. in Phase 2b Imaging Study of Brain Metastasis
BAMF Health dosed the first patient in the U.S. for Radiopharm Theranostics’ Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis.
April 28, 2025
BAMF Health seeks breast cancer patients for groundbreaking imaging study
This non-invasive clinical trial aims to understand the prevalence of a specific biomarker in HR-/HER2+ breast cancer.
April 24, 2025
Fueled by Hope and the Open Road
David was the first person in the United States to receive a new experimental agent to treat pancreatic cancer.
January 22, 2025